Isabella Ciccone is an Associate Editor at Neurology Live. She specializes in medicine and healthcare, covering topics such as medical specialties, diagnostics, and wellness, with a keen focus on both traditional and alternative medicine. Isabella's work has been featured in prominent publications including AJMC - The American Journal of Managed Care, Managed Healthcare Executive, and Patient Care.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Isabella's coverage primarily focuses on neurology and healthcare & pharmaceutical topics, with an emphasis on citing data to support her articles. She may be interested in receiving pitches from experts who can provide insights into the latest research findings, clinical trials, or scientific developments within these areas.
Given the technical nature of Isabella's articles and her reliance on data, she is likely to respond well to pitches that offer expert commentary backed by credible research or statistical evidence. Pitches should demonstrate a clear understanding of the specific medical conditions and treatments discussed in her articles.
Since Isabella does not have a specified geographic focus, she appears open to covering international developments in neurology and healthcare without restriction to a particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Faan, Isabella Ciccone, Amy Gutierrez
The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]
By: Isabella Ciccone, John Corboy
The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]
By: Robert Cochrane, Isabella Ciccone
The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]
By: Isabella Ciccone
Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.
By: Isabella Ciccone, Charbel Moussa
At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]
By: Isabella Ciccone
Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.
By: Isabella Ciccone
Despite missing its primary end point, the SYNAPSE-CMT trial showed improvements in muscle strength and motor function with ignaseclant treatment in patients with Charcot-Marie-Tooth disease.
Here's some of what is coming soon to NeurologyLive® this week.
By: Isabella Ciccone
New phase 2 data showed that riliprubart was associated with sustained improvements in patient-reported outcomes at 76 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
